Viewing Study NCT05155969


Ignite Creation Date: 2025-12-24 @ 10:46 PM
Ignite Modification Date: 2026-03-05 @ 1:11 AM
Study NCT ID: NCT05155969
Status: UNKNOWN
Last Update Posted: 2021-12-14
First Post: 2021-12-08
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Intravenous Esketamine on Prevention of Postoperative Depression in Patients Undergoing Cardiac Surgery
Sponsor: Anshi Wu
Organization:

Study Overview

Official Title: Evaluating the Effect of Subanaesthetic Dose of Esketamine on Prevention of Postoperative Depression in Patients Undergoing Cardiac Surgery:a Randomized, Double-blind, Placebo-controlled Pilot and Feasibility Trial
Status: UNKNOWN
Status Verified Date: 2021-12
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Esketamine is a general anesthetic with anti-depressant effects at subanaesthetic doses. This study hypothesized that intraoperative administration of ketamine would prevent or mitigate postoperative depressive symptoms in surgical patients.
Detailed Description: Single subanaesthetic doses of i.v. esketamine may significantly improve symptoms in psychiatric patients with major depression.

In patients undergoing cardiac surgery, postoperative depressive symptoms are common.

This study hypothesizes that low-dose esketamine has a preventive effect on postoperative depression. However, evidence in this aspect is insufficient. The purpose of this study is to investigate the effect of a subanaesthetic dose of ketamine on POD for patients undergoing cardiac surgery.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: